BiotechTube
Broncus Medical

Broncus Medical

Fremont, United States· Est.
broncus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $115M

Overview

Broncus Medical is a private medical device company pioneering minimally invasive treatments for lung diseases, primarily targeting COPD and lung cancer. Its technology platform centers on catheter-based systems for lung volume reduction and transbronchial ablation of peripheral lung nodules. The company has achieved regulatory approvals (CE Mark, NMPA China) for its flagship LungPoint planning system and Archimedes navigation platform, and is advancing its therapeutic devices through clinical studies. Broncus operates in the large and growing interventional pulmonology market, competing against larger medtech players while seeking to establish its novel therapeutic approaches as standards of care.

Chronic Obstructive Pulmonary Disease (COPD)Lung CancerEmphysema

Technology Platform

Integrated platform for planning (LungPoint VBN), navigating (Archimedes ENB), and treating lung disease via transbronchial catheter-based systems, including thermal vapor ablation (InterVapor) and radiofrequency/microwave ablation (RF-II).

Funding History

3
Total raised:$115M
Series C$70M
Series B$30M
Series A$15M

Opportunities

The large and growing global prevalence of lung cancer and COPD, combined with a clinical shift towards minimally invasive, lung-preserving procedures, creates a significant addressable market.
Expansion of lung cancer screening programs is generating a larger pool of patients with early-stage nodules ideal for transbronchial ablation.
Success in the U.S.
regulatory pathway for its therapeutic devices could unlock the world's largest medical device market.

Risk Factors

Clinical trial failure or regulatory rejection of the RF-II system in the pivotal REACH study would be a major setback.
The company faces intense competition from larger, well-established medical technology corporations with greater resources.
As a private company, it remains dependent on investor funding to sustain operations through lengthy and expensive clinical and regulatory processes.

Competitive Landscape

Broncus competes in the interventional pulmonology space against major players like Johnson & Johnson (acquired Auris Health and its Monarch platform), Medtronic (with its superDimension navigation and ablation systems), and Olympus. For lung volume reduction, it competes with companies like Pulmonx (Zephyr Valves). Its differentiation lies in its focused transbronchial therapeutic ablation approach for cancer and its integrated planning/navigation/therapy platform.

More companies in Digital Health & Biotech SaaS →More companies in United States →